# OnCo record tumour-lysis-syndrome-prevention-and-treatment (protocol). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/protocols/tumour-lysis-syndrome-prevention-and-treatment/>
  a schema:MedicalGuideline ;
  onco:kind "protocol" ;
  schema:identifier "tumour-lysis-syndrome-prevention-and-treatment" ;
  schema:name "Tumour lysis syndrome: risk assessment, prophylaxis and treatment"@en ;
  schema:alternateName "TLS prophylaxis"@en, "tumor lysis syndrome management"@en, "rasburicase or allopurinol"@en, "laboratory TLS"@en, "clinical TLS"@en, "Cairo-Bishop"@en ;
  schema:description "When a fast-growing cancer such as some leukaemias and lymphomas is first treated, many cancer cells can die at once and flood the blood with potassium, phosphate and uric acid, which can damage the kidneys and heart. Teams check who is at risk, give extra fluids and a medicine (allopurinol, or rasburicase for higher risk) before treatment, and check blood tests often in the first days."@en ;
  schema:url <https://onco.cc/protocols/tumour-lysis-syndrome-prevention-and-treatment/> ;
  schema:dateModified "2026-11-11"^^xsd:date ;
  onco:tag "protocol", "acute-oncology", "oncological-emergency", "metabolic" ;
  onco:technologies <https://onco.cc/technologies/car-t/> ;
  onco:drugs <https://onco.cc/drugs/rasburicase/>, <https://onco.cc/drugs/allopurinol/>, <https://onco.cc/drugs/venetoclax/> ;
  onco:terms <https://onco.cc/terms/tumor-lysis-syndrome/>, <https://onco.cc/terms/lymphoma-tx-tumour-lysis/> .